Is MOTS-c Legal in South Carolina? How to Access It Legally
HealthRX.com
MOTS-c has no FDA-approved or listed compounding route
See the public record for MOTS-c
At a glance
- FDA approval / None; not an approved drug or a component of one [1]
- FDA lists / In none of the three categories for state-licensed pharmacies; not on the outsourcing facility list [2][3][4]
- Advisory committee / Voted July 23, 2026 to recommend adding it; advice only [7][5]
- HHS draft policy / Filed October 28, 2026; no enforcement action intended for certain compounded acetate injections [5][6]
- Human data / FDA found no published study in which MOTS-c was given to people; the metabolic and lifespan findings come from mice [1][8]
- Sport / Prohibited at all times by WADA [9]
Why there is no FDA-approved or listed compounding route
MOTS-c is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [1]. FDA's page says state-licensed pharmacies and physicians may compound with a bulk substance only if it complies with a USP or NF monograph, is a component of an FDA-approved product, or appears on FDA's bulks list [4]. MOTS-c meets none of those: it sits in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), is absent from FDA's outsourcing facility list (updated March 21, 2025), and falls outside FDA's category 1 policy [2][3][4].
Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [5]. A draft HHS policy describes possible enforcement discretion for certain MOTS-c acetate injections, but it is not an approval and does not add MOTS-c to any list [5].
What FDA concluded, and where the July 2026 vote fits
FDA's page on bulk substances that may raise significant safety risks (content dated 04/22/2026) places MOTS-c in the 'nominated but withdrawn' table, which holds substances previously in category 2; removal from category 2 was not a finding that it is safe [10]. FDA states it has not identified any human exposure data on drug products containing MOTS-c by any route, and that injectable peptides may pose immunogenicity risk because of aggregation and impurities [10]. In a July 2026 briefing document, FDA staff proposed that neither the free base nor the acetate be added to the pharmacy bulks list, citing inconsistent naming, no impurity, aggregate or endotoxin data, no human safety or effectiveness data and no animal toxicity studies [1]. The Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding it, against staff's recommendation; that vote is advice only, and adding a substance takes formal rulemaking [7][5].
What the October 2026 HHS draft policy says
HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192) naming MOTS-c among six peptides and covering MOTS-c acetate by subcutaneous or intramuscular injection [5][6]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it when the policy's conditions are met, such as a single active ingredient, a patient-specific prescription and an FDA-registered manufacturer with a certificate of analysis [5][6]. The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or product quality issue arises [5].
Questions worth asking
Frequently asked questions
Is MOTS-c legal in South Carolina?
Can a South Carolina pharmacy compound MOTS-c?
Is MOTS-c banned in sport?
References
Show all 11 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.